OBJECTIVE: Interventions in aorto-coronary venous bypass grafts (CABG) can cause acute procedural complications due to distal embolization of debris. In the FIRST (First European Investigation Regarding the Systematic use of the TriActiv device) multicenter trial the distal endovascular protection system TriActiv (Kensey Nash) was evaluated during intervention of CABG. METHODS: 195 patients in 17 centers in Germany with significant disease of a vein graft were enrolled. Inclusion and exclusion criteria were comparable to the SAFER trial. RESULTS: Acute procedural success was achieved in 98% of cases. Aspirated debris was found in 96.5% of patients. Primary endpoints (MACE at 30 days) occurred in 8.7% of all pts. (ITT). No patient died and 7.2% of patients suffered from MI. The rate of early revascularization was 1.5%. Secondary endpoints (MACCE at 30 days) were found in 9.2% and at hospital discharge in 8.7% of patients. CONCLUSIONS: The TriActiv system is safe and effective. Normal post procedural flow can be preserved and the MACE rate is with 8.7% considerably low. The FIRST trial supports the growing belief that PCI of CABG should be performed with protection systems.
OBJECTIVE: Interventions in aorto-coronary venous bypass grafts (CABG) can cause acute procedural complications due to distal embolization of debris. In the FIRST (First European Investigation Regarding the Systematic use of the TriActiv device) multicenter trial the distal endovascular protection system TriActiv (Kensey Nash) was evaluated during intervention of CABG. METHODS: 195 patients in 17 centers in Germany with significant disease of a vein graft were enrolled. Inclusion and exclusion criteria were comparable to the SAFER trial. RESULTS: Acute procedural success was achieved in 98% of cases. Aspirated debris was found in 96.5% of patients. Primary endpoints (MACE at 30 days) occurred in 8.7% of all pts. (ITT). No patient died and 7.2% of patients suffered from MI. The rate of early revascularization was 1.5%. Secondary endpoints (MACCE at 30 days) were found in 9.2% and at hospital discharge in 8.7% of patients. CONCLUSIONS: The TriActiv system is safe and effective. Normal post procedural flow can be preserved and the MACE rate is with 8.7% considerably low. The FIRST trial supports the growing belief that PCI of CABG should be performed with protection systems.
Authors: M K Hong; R Mehran; G Dangas; G S Mintz; A J Lansky; A D Pichard; K M Kent; L F Satler; G W Stone; M B Leon Journal: Circulation Date: 1999-12-14 Impact factor: 29.690
Authors: Donald S Baim; Dennis Wahr; Barry George; Martin B Leon; Joel Greenberg; Donald E Cutlip; Unsal Kaya; Jeffrey J Popma; Kalon K L Ho; Richard E Kuntz Journal: Circulation Date: 2002-03-19 Impact factor: 29.690
Authors: Marco Roffi; Debabrata Mukherjee; Derek P Chew; Deepak L Bhatt; Leslie Cho; Mark A Robbins; Khaled M Ziada; Danielle M Brennan; Stephen G Ellis; Eric J Topol Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Joseph P Carrozza; Michael Mumma; Jeffrey A Breall; Aland Fernandez; Eugene Heyman; Christopher Metzger Journal: J Am Coll Cardiol Date: 2005-10-10 Impact factor: 24.094
Authors: R M Califf; A E Abdelmeguid; R E Kuntz; J J Popma; C J Davidson; E A Cohen; N S Kleiman; K W Mahaffey; E J Topol; C J Pepine; R J Lipicky; C B Granger; R A Harrington; B E Tardiff; B S Crenshaw; R P Bauman; B D Zuckerman; B R Chaitman; J A Bittl; E M Ohman Journal: J Am Coll Cardiol Date: 1998-02 Impact factor: 24.094
Authors: Joseph P Carrozza; Christophe Caussin; Gregory Braden; Peter Braun; Forde Hansell; Robin Fatzinger; Greg Walters; William Kussmaul; Jeffrey Breall Journal: Am Heart J Date: 2005-06 Impact factor: 4.749
Authors: R N Piana; G Y Paik; M Moscucci; D J Cohen; C M Gibson; A D Kugelmass; J P Carrozza; R E Kuntz; D S Baim Journal: Circulation Date: 1994-06 Impact factor: 29.690
Authors: P Golino; F Piscione; C R Benedict; H V Anderson; M Cappelli-Bigazzi; C Indolfi; M Condorelli; M Chiariello; J T Willerson Journal: N Engl J Med Date: 1994-02-24 Impact factor: 91.245
Authors: Ibrahim Akin; Marcus Wiemer; Steffen Schneider; Jochen Senges; Matthias Hochadel; Gert Richardt; Mohamed Abdel-Wahab; Karl-Heinz Kuck; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2011-11-13 Impact factor: 5.460